Virpax Pharmaceuticals' Matthew Barnes to Speak at Key Conference
Virpax Pharmaceuticals to Showcase Innovations at Key Conference
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) is excited to announce that Matthew Barnes, the senior director of portfolio management, will present at the Outsourcing in Clinical Trials Conference. This event is a prominent gathering in the clinical trial community focused on sharing advancements and innovations.
About the Outsourcing in Clinical Trials Conference
The Outsourcing in Clinical Trials (OCT) Conference is renowned globally for bringing industry leaders together. Each year, over 1,000 professionals gather to discuss effective strategies for optimizing clinical trial timelines and managing operational costs. This conference serves as a platform for collaborative learning and innovation within the biotech and pharmaceutical sectors.
Collaboration for Success in Clinical Trials
OCT provides a valuable environment for various stakeholders in the healthcare industry, including trial sponsors, medical device manufacturers, and solution providers. Participants benefit from networking opportunities that facilitate collaborations aimed at achieving success in clinical trials. The sharing of success stories and strategies contributes to a more efficient clinical trial process, ensuring better outcomes for patients.
Acknowledging Achievements in Research
Moreover, Virpax takes this opportunity to commend Dr. Sheila Mathias, the Chief Scientific Officer, alongside Matthew Barnes for their recent publications in the DIA Global Forum and the OCT Handbook 2025. These articles highlight their contributions to advancing drug delivery systems and pain management.
Virpax's Focus on Non-Addictive Pain Management Solutions
Virpax is dedicated to developing innovative, non-addictive solutions for pain management, central nervous system disorders, and related health issues. The company is particularly focused on receiving FDA approvals for two unique prescription drug candidates. One is Probudur™, a single injection liposomal bupivacaine formulation targeting post-operative pain, while the other is Envelta™, designed for managing acute and chronic pain, including cancer-related ailments.
Expanding Innovative Drug Delivery Approaches
In addition to these two candidates, Virpax is also advancing NobrXiol™, an intranasal formulation of pharmaceutical-grade cannabidiol (CBD), aimed at treating rare pediatric epilepsy. This innovative approach underscores the potential of Cannabidiol in addressing complex health challenges. The company has established important cooperative research agreements with renowned institutions, such as the National Institutes of Health (NIH) and the Department of Defense (DOD), which bolster their research and development efforts.
Future Projects and Aspirations
Virpax is also exploring partnerships for two of its nonprescription candidates, including AnQlar, engineered to inhibit viral replication from influenza and SARS-CoV-2, emphasizing the company's ambition to contribute to global health challenges. Additionally, Epoladerm™, a topical decofenac spray, is being developed for effective pain management related to osteoarthritis.
Frequently Asked Questions
Who is Matthew Barnes?
Matthew Barnes is the senior director of portfolio management at Virpax Pharmaceuticals, responsible for overseeing the company’s drug development projects.
What is the focus of the Outsourcing in Clinical Trials Conference?
This conference emphasizes collaboration among clinical trial professionals to share best practices and innovative strategies that help streamline clinical trial processes.
What innovative products is Virpax working on?
Virpax is developing several non-addictive pain management products, including Probudur™, Envelta™, and NobrXiol™, targeting various pain management needs.
How does Virpax support research and development?
Virpax collaborates with prestigious organizations like the NIH and DOD through cooperative research agreements to enhance their R&D capabilities.
What is the mission of Virpax Pharmaceuticals?
Virpax aims to provide safe, effective, and non-addictive healthcare solutions for pain management and related health disorders through innovative drug delivery technologies.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.